Abstract
Vaccination provides a powerful tool for mitigating and controlling the COVID-19 pandemic. However, a number of factors reduce these potential benefits. The first problem arises from heterogeneities in vaccine supply and uptake: from global inequities in vaccine distribution, to local variations in uptake derived from vaccine hesitancy. The second complexity is biological: though several COVID-19 vaccines offer substantial protection against infection and disease, ‘breakthrough’ reinfection of vaccinees (and subsequent retransmission from these individuals) can occur, driven especially by new viral variants. Here, using a simple epidemiological model, we show that the combination of infection of remaining susceptible individuals and breakthrough infections of vaccinees can have significant effects in promoting infection of invading variants, even when vaccination rates are high and onward transmission from vaccinees relatively weak. Elaborations of the model show how heterogeneities in immunity and mixing between vaccinated and unvaccinated sub-populations modulate these effects, underlining the importance of quantifying these variables. Overall, our results indicate that high vaccination coverage still leaves no room for complacency if variants are circulating that can elude immunity, even if this happens at very low rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by the Natural Sciences and Engineering Research Council of Canada through a Postgraduate-Doctoral Scholarship (C.M.S.-R.); a Charlotte Elizabeth Procter Fellowship of Princeton University (C.M.S.-R.), the James S. McDonnell Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and Multi-scale Systems (S.A.L.); the C3.ai Digital Transformation Institute and Microsoft Corporation (S.A.L.); Gift from Google, LLC (S.A.L.); the National Science Foundation (CNS-2041952, CCF2142997, and CCF1917819) (S.A.L.); the US Centers for Disease Control and Prevention (B.T.G.); and the Flu Lab (B.T.G.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This manuscript contains no data
